Bradenton, Florida.,, June 4, 2025 / Prnewswire / – Continuity biosciences, LLCAn Advanced Drug Delivery Technologies developer announced today the acquisition of Focal Medical, Inc.A North Carolina– Biopharmaceutical chemotherapy based on a pioneer specific to the site using iontophoresis. Acquisition represents a key step in continuity strategy to become a leader in therapy targeted by the device for intractable solid tumors.
Founded by leading scientists and clinicians, Focal Medical has developed a owner platform that offers chemotherapy directly to tumors using ontophoresis– This little invasive technique uses a light electric current to cause therapeutic compounds in targeted tissues. This method improves the local concentration of drugs while minimizing systemic toxicity, a critical need for the treatment of pancreatic cancers and other solid tissues.
The main candidate of the main Focal Medical product, an iontophoresis device led by gemcitabine therapy for pancreatic cancer, was eliminated by the US Food and Drug Administration (FDA) through a new drug application (IND). Phase 1b Clinical trials are expected to start later this year.
“This is a transformative step for continuity biosciences,” said Ramakrishna VenugopalanPHD, MBA, Managing Director of Continuity Biosciences. “The Focal Medical approach to localized delivery of drugs aligns perfectly with our vision to improve bioavailability, reduce systemic exposure and provide better results for patients. We are delighted to provide this promising platform in our portfolio and in the clinic.”
Thanks to the acquisition, continuity biosciences obtains a patent technology platform, an iontophoresis technology platform and specialized agreements, scientific know-how and license agreements with agreements with agreements North Carolina University in Chapel Hill. In addition, key scientific staff and focal leadership will join continuity, further improving their internal capacities. A research and development installation dedicated to Cary, nc This supports the progress in progress and the advancement of pipelines is also part of the acquisition and will be extended to support other delivery platforms.
Visionary founders leading innovation
Focal Medical was co -founded by:
- Jen Jen YehMDa surgical oncologist and professor at UNC-Chapel hill With joint meetings in surgery and pharmacology. She is the assistant dean of translational research at the UNC medical school and associate director of translational research in the full cancer center of the UNC Lineberger. Dr. Yeh is widely recognized for its expertise in pancreatic cancer and translational oncology.
- Joseph DesimonePHDA award -winning chemist, entrepreneur and academic University of Stanford. It is known worldwide for its breakthroughs in materials, nanomedicine and advanced manufacturing, including 3D printing.
Their iontophoresis system is designed to deliver GemcitabineA chemotherapy agent approved by the FDA, directly in pancreatic tumors. The traditional systemic administration of gemcitabine is often limited by poor penetration of tumors and significant toxicity. The focal approach bypassing these limits by delivering the drug directly to the tumor site with high precision and minimum systemic toxicity.
“After almost a decade of R&D, we are delighted to join the continuity bioscience family,” said Tony WarInterim CEO of Focal Medical. “We are grateful to our founders, scientific collaborators and investors who helped us reach this pivotal point. The partnership with continuity guarantees that this new therapy is advancing in the clinic where it has the potential to help patients confronted with one of the deadliest cancers.”
This acquisition strengthens the commitment of continuity biosciences to create a diversified portfolio of clinically significant drug platforms and signals a decisive development to become a leader in the clinical stage in therapy specific to the site.
On continuity biosciences
Continuity Biosciences, LLC is a biopharmaceutical company developing advanced technologies of drug administration which deal with the limits of conventional therapeutic administration. With operations in Bradenton, fl; Houston, tx; Raleigh, nc; And Torino, ItalyThe company focuses on combined drug platforms for chronic and complex conditions.
Visit: www.continuitybiosciences.com
About focal medicine
Focal Medical, Inc. develops energy -based chemotherapy administration systems that allow direct application of drugs to tumor sites. Its mission is to improve efficiency and reduce toxicity in the treatment of solid tumors, with a first emphasis on pancreatic cancer.
Visit: www.focalmedical.co
Source continuity biosciences LLC
